Latest StemPoint Capital LP Stock Portfolio
StemPoint Capital LP Performance:
2024 Q3: 5.28%YTD: 13.94%
Performance for 2024 Q3 is 5.28%, and YTD is 13.94%.
About StemPoint Capital LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, STEMPOINT CAPITAL LP reported an equity portfolio of $334 Millions as of 30 Sep, 2024.
The top stock holdings of STEMPOINT CAPITAL LP are SNDX, ROIV, MRUS. The fund has invested 10% of it's portfolio in SYNDAX PHARMACEUTICALS INC and 9.6% of portfolio in ROIVANT SCIENCES LTD.
The fund managers got completely rid off IMMUNOCORE HLDGS PLC (IMCR), MERCK & CO INC (MRK) and GSK PLC stocks. They significantly reduced their stock positions in EDGEWISE THERAPEUTICS INC (EWTX), ARCELLX INC (ACLX) and CRINETICS PHARMACEUTICALS IN (CRNX). STEMPOINT CAPITAL LP opened new stock positions in BRISTOL-MYERS SQUIBB CO (BMY), INCYTE CORP (INCY) and DAY ONE BIOPHARMACEUTICALS I (DAWN). The fund showed a lot of confidence in some stocks as they added substantially to PRAXIS PRECISION MEDICINES I (PRAX).
The top stock holdings of STEMPOINT CAPITAL LP are SNDX, ROIV, MRUS. The fund has invested 10% of it's portfolio in SYNDAX PHARMACEUTICALS INC and 9.6% of portfolio in ROIVANT SCIENCES LTD.
The fund managers got completely rid off IMMUNOCORE HLDGS PLC (IMCR), MERCK & CO INC (MRK) and GSK PLC stocks. They significantly reduced their stock positions in EDGEWISE THERAPEUTICS INC (EWTX), ARCELLX INC (ACLX) and CRINETICS PHARMACEUTICALS IN (CRNX). STEMPOINT CAPITAL LP opened new stock positions in BRISTOL-MYERS SQUIBB CO (BMY), INCYTE CORP (INCY) and DAY ONE BIOPHARMACEUTICALS I (DAWN). The fund showed a lot of confidence in some stocks as they added substantially to PRAXIS PRECISION MEDICINES I (PRAX).
StemPoint Capital LP Annual Return Estimates Vs S&P 500
Our best estimate is that STEMPOINT CAPITAL LP made a return of 5.28% in the last quarter. In trailing 12 months, it's portfolio return was 39.89%.
New Buys
| Ticker | $ Bought |
|---|---|
| bristol-myers squibb co | 14,244,200 |
| incyte corp | 8,559,290 |
| day one biopharmaceuticals i | 7,062,200 |
| acelyrin inc | 6,497,020 |
| soleno therapeutics inc | 6,219,210 |
| keros therapeutics inc | 5,048,020 |
| zura bio ltd | 4,239,320 |
| terns pharmaceuticals inc | 3,747,340 |
New stocks bought by StemPoint Capital LP
Additions
| Ticker | % Inc. |
|---|---|
| praxis precision medicines i | 197 |
Additions to existing portfolio by StemPoint Capital LP
Reductions
| Ticker | % Reduced |
|---|---|
| edgewise therapeutics inc | -96.33 |
| arcellx inc | -89.3 |
| crinetics pharmaceuticals in | -80.6 |
| janux therapeutics inc | -73.42 |
| immunovant inc | -66.84 |
| perspective therapeutics inc | -65.38 |
| applied therapeutics inc | -64.85 |
| pyxis oncology inc | -64.65 |
StemPoint Capital LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| kalvista pharmaceuticals inc | -17,358,200 |
| larimar therapeutics inc | -10,213,100 |
| fulcrum therapeutics inc | -8,636,150 |
| black diamond therapeutics i | -6,283,530 |
| immunocore hldgs plc | -23,001,200 |
| gsk plc | -18,936,800 |
| spyre therapeutics inc | -7,074,160 |
| celldex therapeutics inc new | -10,693,400 |
StemPoint Capital LP got rid off the above stocks
Sector Distribution
STEMPOINT CAPITAL LP has about 86.8% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 86.8 |
| Others | 13.2 |
Market Cap. Distribution
STEMPOINT CAPITAL LP has about 7.4% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 37.8 |
| SMALL-CAP | 35.4 |
| UNALLOCATED | 16.1 |
| LARGE-CAP | 7.4 |
| MICRO-CAP | 2.1 |
| NANO-CAP | 1.2 |
Stocks belong to which Index?
About 54.4% of the stocks held by STEMPOINT CAPITAL LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 47.6 |
| Others | 45.6 |
| S&P 500 | 6.8 |
StemPoint Capital LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of StemPoint Capital LP
STEMPOINT CAPITAL LP has 50 stocks in it's portfolio. About 56% of the portfolio is in top 10 stocks. CABA proved to be the most loss making stock for the portfolio. APLT was the most profitable stock for STEMPOINT CAPITAL LP last quarter.
Last Reported on: 13 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 1.50 | 60,076 | 5,016,950 | reduced | -89.3 | ||
| AGLE | spyre therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALKS | alkermes plc | 0.41 | 48,918 | 1,369,220 | new | |||
| APLT | applied therapeutics inc | 3.96 | 1,554,590 | 13,214,000 | reduced | -64.85 | ||
| ARQT | arcutis biotherapeutics inc | 4.95 | 1,778,320 | 16,538,400 | reduced | -7.9 | ||
| ATXS | astria therapeutics inc | 0.18 | 56,287 | 618,876 | new | |||
| AUTL | autolus therapeutics plc | 2.84 | 2,616,600 | 9,498,260 | reduced | -50.87 | ||
| BBIO | bridgebio pharma inc | 0.72 | 94,885 | 2,415,770 | new | |||
| BDTX | black diamond therapeutics i | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BMY | bristol-myers squibb co | 4.26 | 275,303 | 14,244,200 | new | |||
| CABA | cabaletta bio inc | 1.81 | 1,278,440 | 6,034,260 | reduced | -45.74 | ||
| CAPR | capricor therapeutics inc | 0.43 | 93,638 | 1,424,230 | new | |||
| CLDX | celldex therapeutics inc new | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CNTA | centessa pharmaceuticals plc | 0.40 | 83,662 | 1,337,760 | new | |||
| CRBP | corbus pharmaceuticals hldgs | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CRNX | crinetics pharmaceuticals in | 3.27 | 213,815 | 10,925,900 | reduced | -80.6 | ||
| CYTK | cytokinetics inc | 0.23 | 14,464 | 763,699 | new | |||
| DAWN | day one biopharmaceuticals i | 2.11 | 506,978 | 7,062,200 | new | |||
| DNLI | denali therapeutics inc | 2.46 | 282,050 | 8,216,120 | reduced | -43.82 | ||
| EWTX | edgewise therapeutics inc | 0.16 | 19,900 | 531,131 | reduced | -96.33 | ||